Leverage patient-centric Real-World Evidence (RWE) to accelerate the patient and market access

    Real-World Evidence in Rare Diseases: Accelerating Market Access

    26 – 27 September 2022, live online training

    Summary

    This unique training focuses on leveraging patient-centric Real-World Evidence (RWE) to accelerate the patient and market access of innovative and potentially transformative Orphan Medicinal Products (OMPs). Delegates will address the challenge of early market access based on fewer and less mature data, with the creation of an Early Value Proposition and a Patient-Centric Evidence Generation Plan that comprehensively support value demonstration, product positioning, and that meet stakeholders’ requirements.

    Learning Objectives

    • Why are market access opportunities and challenges for OMPs different from other drugs?
    • How to collaborate with patients & caregivers in rare conditions to generate patient-meaningful outcomes?
    • Leveraging applications of RWE for pricing and access success and throughout the lifecycle
    • To mitigate payer uncertainty by addressing the challenge of early market access with accelerated approvals and fewer clinical data
    • How to develop a next-generation market access strategy with a life-cycle full spectrum evidence generation plan that maximizes product value from launch to loss of exclusivity?
    • To differentiate and succeed in the increasingly competitive rare disease space with a ‘fast to patient’ approach

    Key Topics

    • Opportunities and Challenges in Orphan Medicinal Products (OMPs)
    • Rare Patient Empowerment & Involvement
    • Real-World Evidence (RWE) Throughout the Value Chain
    • Real-World Case Examples
    • Early Value Proposition and Evidence Generation Planning
    • Next-Generation OMP Market Access Strategies

    Who should attend?

    C-level executives, Senior business development strategists, Portfolio executives, Pricing and market access executives, Medical affairs executives, Marketing and commercial executives, Patient advocates, Epidemiologists, Outcomes researchers and health economists, Big data and RWE researchers, Clinical and regulatory executives interested in incorporating value and access early in development

    Past participants

    • IVS Head, AstraZeneca
    • Global Clinical Leader, Bayer
    • Head of Market Access & Pricing, Merck Group
    • Rare Diseases Lead Adriatic, Pfizer
    • Patient Value & Acces Head, Takeda

    Our online training experience includes

    • Our client zone – a single source for all training materials as well as pre and post-training communication
    • Live interactive format via the Zoom platform
    • Direct interaction with the trainer
    • Q&As, case studies, polls
    • Revisit recorded sessions for 30 days
    • Digital and LinkedIn certificates

    Follow-up Session

    This half-day follow-up workshop aims to enhance the RWE knowledge gained by participants in the main course with a highly interactive session of practical solutions based on current demonstrator cases in rare conditions (successes and failures). The Follow-up session is only available and suitable for participants, who took the main course.

    Trainers

    ORPHA Strategy Consulting, CEO
    David Schwicker has biopharmaceutical consulting expertise spanning more than 25 years. Founder of ORPHA Strategy Consulting, and former Vice President with PAREXEL International in the United States. David is a sought-after expert for accelerating marketing authorization, time to launch, early patient and market access of ATMPs.
    Online Participation - Main Session
    1 500 Price incl. VAT: 1 500
    Equivalent of approx. 1 609 USD.
    The price calculation in USD is informative and might slightly differ from your bank exchange rate
    .

    Price per delegate includes:

    Online participation at Main Session

    Online workbook & materials

    Access to client zone

    Digital & LinkedIn Certificates

    Online Participation - Main Session + Follow-up Session
    2 000 Price incl. VAT: 2 000
    Equivalent of approx. 2 145 USD.
    The price calculation in USD is informative and might slightly differ from your bank exchange rate
    .

    Price per delegate includes:

    Online participation at the Main session on 26 - 27 September

    Online participation at the Follow-up session on 10 October

    Online workbook & materials

    Access to client zone

    Digital & LinkedIn certificates

    PC, microphone, camera, stable internet connection and the Zoom application.

    Yes, we will make every effort to ensure best possible interaction. You will see the slides, interact with the trainer and fellow participants. Questions and group exercises will be facilitated through the online meeting platform.

    Yes, you can transfer the registration to a colleague at any time.

    Yes, you may transfer your registration to a different event up to one month before the scheduled dates, provided the training fee has been paid in full.

    pharma learning leader

    Lydia Makori

    l.makori@symmetric.events
    +421 222 200 543

    Training Details
    • Start Date
      26. September 2022
      01:00 PM Vienna time
      12:00 PM London time
      07:00 AM New York time
      04:00 AM Los Angeles time
    • End Date
      27. September 2022
    What participants said about this course

    "Extremely knowledgeable speaker, the whole meeting was great"
    Evidence Generation Lead, UCB

    "Trainer very clear and prepared. Excellent meeting."
    Health Economics & Market Access Manager, Pfizer Hellas

    "Great expertise of the speaker and practical examples how this has been done by other companies. Also outlook, where the trends in RWE are (likely) going."
    Head Public Affairs & Public Policy, Takeda